Breaking News Instant updates and real-time market news.

SGEN

Seattle Genetics

$65.29

1.57 (2.46%)

16:04
10/25/18
10/25
16:04
10/25/18
16:04

Seattle Genetics sees Q4 Adcetris sales $128M-$133M

Sees FY18 Adcetris net product sales $473M-$478M.

  • 25

    Oct

  • 12

    Nov

SGEN Seattle Genetics
$65.29

1.57 (2.46%)

10/03/18
LEHM
10/03/18
NO CHANGE
Target $95
LEHM
Overweight
Seattle Genetics price target raised to $95 from $80 at Barclays
Barclays analyst Geoff Meacham raised his price target for Seattle Genetics to $95 saying this week's positive Adcetris E-2 data in frontline CD30-expressing peripheral T-cell lymphoma was another "win" for the company's core Adcetris franchise. The analyst thinks Adcetris is likely to capture his sixth indication and he keeps an Overweight rating on the shares. He we increased his Adcetris peak sales forecast by $550, representing 2022 product sales of $1.44B, above the consensus estimate of $1.31B.
10/02/18
RBCM
10/02/18
NO CHANGE
Target $98
RBCM
Outperform
Seattle Genetics price target raised to $98 from $90 at RBC Capital
RBC Capital analyst Kennen MacKay raised his price target on Seattle Genetics to $98 and kept his Outperform rating, saying its ECHELON-2 trial "exceeded best case scenario" with a "surprise" overall survival benefit. The analyst notes that the results were a "clean win with E-2's magnitude of PFS benefit", raising his probability of success for the program to 100% from 75%.
10/01/18
PIPR
10/01/18
NO CHANGE
Target $71
PIPR
Neutral
Seattle Genetics positive data already priced into shares, says Piper Jaffray
Piper Jaffray analyst Joseph Catanzaro believes the positive Phase III Echelon-2 trial announced this morning by Seattle Genetics "was fully baked into" the shares. The analyst remains comfortable with his Adcetris estimates pending the full data and keeps a Neutral rating on the shares with a $71 price target. The stock in early trading is up 3%, or $2.00, to $79.12.
09/26/18
JPMS
09/26/18
NO CHANGE
Target $85
JPMS
Overweight
Seattle Genetics price target raised to $85 from $77 at JPMorgan
JPMorgan analyst Cory Kasimov raised his price target for Seattle Genetics to $85 saying he's bullish on the potential success of ECHELON-2, which is expected to readout in Q4. The analyst, however, thinks expectations from investors are "relatively high." Nevertheless, another successful readout and material line extension for Adcetris could help maintain the stock's "impressive recent momentum," Kasimov tells investors in a research note. He keeps an Overweight rating on Seattle Genetics.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.